HCW BIOLOGICS INC HCWB
COM · Common Stock · CUSIP 40423R303
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersMiramar, FL
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 1.8m as of 2026-08-12, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $4.98.
Biggest buyers
| JANE STREET GROUP, LLC | New | +52.1k |
| CITADEL ADVISORS LLC | New | +19.9k |
| HRT FINANCIAL LP | New | +13.6k |
| VANGUARD FIDUCIARY TRUST CO | New | +6.5k |
| Tower Research Capital LLC (TRC) | New | +4.1k |
| Connective Capital Management, LLC | New | +3.3k |
| VANGUARD CAPITAL MANAGEMENT LLC | New | +2.0k |
| Golden State Wealth Management, LLC | New | +1.7k |
| BARCLAYS PLC | New | +191 |
| Caitong International Asset Management Co., Ltd | New | +11 |
Biggest sellers
| None |
Insider purchases and sales since 1 Apr 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q4 2024 | 0 | — | 0 | — | — |
| Q1 2025 | 0 | — | 0 | — | — |
| Q2 2025 | 6 | $3.0m | 0 | — | — |
| Q3 2025 | 0 | — | 0 | — | — |
| Q4 2025 | 0 | — | 0 | — | — |
| Q1 2026 | 0 | — | 0 | — | — |
| Q2 2026 | 3 | — | 0 | — | — |
| Q3 2026 | 3 | $80.2k | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2026-07-29 | Wong Hing C Chief Executive Officer, director | Bought | $60.1k23.2k shares |
| 2026-07-29 | GARRETT SCOTT T Director · By LLC | Bought | $20.0k7.7k shares |
| 2026-07-29 | Flowers Lee SVP of Business Development | Bought | $20.0k7.7k shares |
| 2026-05-22 | Byam Rebecca Chief Financial Officer | Bought | —14.2k shares |
| 2026-05-22 | GARRETT SCOTT T Director · By LLC | Bought | —177.9k shares |
| 2026-05-22 | Wong Hing C Chief Executive Officer, director | Bought | —113.9k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| JANE STREET GROUP, LLC 0.00% of their portfolio | 52.1k $260.2k | New |
| CITADEL ADVISORS LLC 0.00% of their portfolio | 19.9k $99.5k | New |
| HRT FINANCIAL LP 0.00% of their portfolio | 13.6k $67.0k | New |
| VANGUARD FIDUCIARY TRUST CO 0.00% of their portfolio | 6.5k $32.5k | New |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 4.1k $20.5k | New |
| Connective Capital Management, LLC 0.01% of their portfolio | 3.3k $16.7k | New |
| VANGUARD CAPITAL MANAGEMENT LLC 0.00% of their portfolio | 2.0k $10.0k | New |
| Golden State Wealth Management, LLC 0.00% of their portfolio | 1.7k $8.3k | New |
| BARCLAYS PLC 0.00% of their portfolio | 191 $953 | New |
| Caitong International Asset Management Co., Ltd 0.00% of their portfolio | 11 $10 | New |
| OSAIC HOLDINGS, INC. 0.00% of their portfolio | 4 $20 | New |
| UBS Group AG 0.00% of their portfolio | 1 $5 | New |